35 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
and building our pipeline through strategic partnerships and M&A. To achieve our ambitious goals, we evaluate and access external innovation. We … business actions impact both society and our financial performance. To determine our key goals and priorities, we conducted an impact materiality
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
specific goals for remuneration are: to offer competitive opportunities for talented individuals by benchmarking against appropriate peer groups … , as well as sustainable progress towards long-term strategic goals, taking into account the management of unforeseen developments and broader
6-K
EX-99.6
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
Development Goals (SDG’s). In accordance with article 3:75, §1, first paragraph, 6° of the Code of companies and associations, we do not express an opinion
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
, statements relating to interactions with regulatory authorities, and statements related to our portfolio goals, business plans, and sustainability plans
6-K
EX-99.1
i741b
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
0c1xqjxb zmj
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.2
gfg8m3kbv85a9hbmwzm
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
5u4m7a94 ugp5e11
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
bfi8 kddfm6x4
31 Mar 23
Current report (foreign)
6:05am
6-K
EX-99.1
3gs50r
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
u90ijzo1 ai30z8enoy
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
4tc810by
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
6qkmxiarwcq27sysy7
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
m61nrypzvit xj5
31 May 22
Current report (foreign)
1:39pm
6-K
EX-99.3
183wwwg44
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
8a23 zhp260
7 Feb 22
Current report (foreign)
2:40pm
6-K
EX-99.1
jb38wk5707mn9agqn
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
6-K
EX-99.1
x90es12 x2
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am